JAMA Oncol
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP)
doi: 10.1001/jamaoncol.2026.1924
